15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2.9B | $538M | 67.4% | 16.3% | $589M | — | $526M |
| 2024 | $2.5B | $103M | 58.9% | 6.6% | $405M | — | $784M |
| 2023 | $1.6B | $123M | 65.1% | 8.5% | $165M | — | — |
| 2022 | $1.0B | $190M | 74.2% | 22.3% | $104M | — | — |
| 2021 | $958M | $149M | 75.0% | 17.9% | $219M | — | — |
| 2020 | $789M | $102M | 72.4% | 14.1% | $135M | — | — |
| 2019 | $785M | $155M | 77.1% | 21.9% | $101M | — | $195M |
| 2018 | $713M | $156M | 77.6% | 23.7% | $122M | — | $140M |
| 2017 | $636M | $107M | 76.3% | 25.4% | $108M | — | $119M |
| 2016 | $564M | $104M | 76.1% | 27.3% | $107M | — | $67M |
| 2015 | — | $113M | — | — | $73M | — | $58M |
| 2014 | — | $92M | — | — | $54M | — | $82M |
| 2013 | — | $69M | — | — | $70M | — | $90M |
| 2012 | — | $74M | — | — | $52M | — | $212M |
| 2011 | — | $61M | — | — | $54M | — | $143M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $760M | $124M | 69.2% | 19.8% | $163M | — | $561M |
| Dec '25 | $826M | $141M | 68.4% | 20.5% | $202M | — | $526M |
| Sep '25 | $769M | $119M | 67.2% | 17.9% | $214M | — | — |
| Jun '25 | $745M | $203M | 66.6% | 10.2% | $31M | — | — |
| Mar '25 | $598M | $75M | 67.3% | 16.2% | $141M | — | — |
| Dec '24 | $657M | $27M | 59.9% | 9.2% | $193M | — | $784M |
| Sep '24 | $626M | $52M | 56.8% | 7.7% | $162M | — | — |
| Jun '24 | $630M | $32M | 58.7% | 7.9% | $26M | — | — |
| Mar '24 | $607M | -$7M | 60.2% | 1.3% | $24M | — | — |
| Dec '23 | $617M | $15M | 56.9% | 1.6% | $82M | — | — |
| Sep '23 | $384M | $998000 | 64.7% | 0.1% | $29M | — | — |
| Jun '23 | $292M | $58M | 73.8% | 22.7% | $17M | — | — |
| Mar '23 | $277M | $49M | 74.4% | 20.4% | $37M | — | — |
| Dec '22 | $274M | $50M | 74.3% | 19.7% | $46M | — | — |
| Sep '22 | $254M | $47M | 74.2% | 23.5% | $21M | — | — |
| Jun '22 | $264M | $55M | 74.0% | 25.7% | $13M | — | — |
| Mar '22 | $231M | $38M | 74.3% | 20.1% | $25M | — | — |
| Dec '21 | $250M | $15M | 75.3% | 7.3% | $59M | — | — |
| Sep '21 | $230M | $47M | 74.5% | 23.2% | $59M | — | — |
| Jun '21 | $251M | $42M | 74.6% | 18.3% | $51M | — | — |
How the market has priced GMED against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Globus Medical Inc's revenue has grown 30.1% per year, and net income grown 39.4% per year. These are computed facts, not advice.
As of FY2025, Globus Medical Inc reported — of total debt against $526M of cash.
In FY2025, gross margin was 67.4%, operating margin 16.3%, and net margin 18.3%.
As of Jun '26, Globus Medical Inc traded at a price-to-earnings ratio of about 21.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.